Estimating the health consequences of replacing cigarettes with nicotine inhalers

Tobacco Control

Volumn 12, Issue 2, 2003, Pages 124-132

  Sumner II, W ^a  

^a Division of General Medical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIGARETTE SMOKE CONDENSATE; NICOTINE;

ARTICLE; CIGARETTE SMOKING; COMPUTER PROGRAM; DATA ANALYSIS; DISEASE CONTROL; HAZARD ASSESSMENT; HEALTH HAZARD; INHALER; PREDICTION; PREVALENCE; PUBLIC HEALTH SERVICE; RISK ASSESSMENT; SMOKING CESSATION; UNITED STATES; ADULT; AGED; FEMALE; HEALTH STATUS; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; NEBULIZER; PROGNOSIS; RISK FACTOR; SMOKING;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEALTH STATUS; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; NICOTINE; PREVALENCE; PROGNOSIS; RISK FACTORS; SMOKING; SMOKING CESSATION;

EID: 0141663499     PISSN: 09644563     EISSN: None     Source Type: Journal    
DOI: 10.1136/tc.12.2.124     Document Type: Article

References (79)

1. Benowitz N. Summary: risks and benefits of nicotine. In: Benowitz, ed. Nicotine safety and toxicity. New York: Oxford University Press, 1998:185-95.
2. Institute of Medicine. Clearing the smoke: assessing the science base for tobacco harm reduction. Washington DC: National Academy Press, 2001.
3. US Department of Health and Human Services. The health consequences of smoking: the changing cigarette. A report of the Surgeon General, 1981. Rockville, Maryland: Public Health Service, Office of the Assistant Secretary for Health, Office on Smoking and Health, 1981. (DHHS Publication No (PHS) 81-50156.)
4. Kozlowski LT, Strasser AA, Giovino GA, et al. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tobacco Control 2001;10:201-3.
5. McNeil A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction 2001;96:1757-68.
6. Warner KE, Slade J, Sweanor DT. The emerging market for long-term nicotine maintenance. JAMA 1997;278:1087-92.
7. Warner KE, Peck CC, Woosley RL, et al. Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J 1998;53(suppl):1-8.
8. Slade J, Henningfield JE. Tobacco product regulation: context and issues. Food Drug Law J 1998;53(suppl):43-74.
9. Page JA. Federal regulation of tobacco products and products that treat tobacco dependence: are the playing fields level? Food Drug Law J 1998;53(suppl):11-42.
10. Henningfield JE, Slade J. Tobacco-dependence medications: public health and regulatory issues. Food Drug Law J 1998;53(suppl):75-114.
11. Hoffmann D, Hoffmann I, El-Bayoumy K. The less harmful cigarette: a controversial issue, a tribute to Ernst L. Wynder. Chem Res Toxicol 2001;14:767-90.
12. Hoffmann D, Hoffmann I. The changing cigarette, 1950-1995. J Toxicol Environ Health 1997;50:307-64.
13. Gori GB. Low-risk cigarettes: a prescription. Science 1976;194:1243-6.
14. Stapleton JA, Russell MA, Sutherland G, et al. Nicotine availability from Eclipse tobacco-heating cigarette. Psychopharmacology (Berl) 1998;139:288-90.
15. Pierce JA, Gilpin EA. Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation. JAMA 2002;288:1260-4.
16. Schuh KJ, Schuh LM, Henningfield JE, et al. Nicotine nasal spray and vapor inhaler: abuse liability assessment. Psychopharmacology (Berl) 1997;130:352-61.
17. Russell MA, Jarvis MJ, Sutherland G, et al. Nicotine replacement in smoking cessation. Absorption of nicotine vapor from smoke-free cigarettes. JAMA 1987;257:3262-5.
18. Rose J, Behm F, Turner J. 15 August 1995. USA patent 5441060.
19. Russell MA. The future of nicotine replacement. Br J Addict 1991;86:653-8.
20. Rodu B. An alternative approach to smoking control. Am J Med Sci 1994;308:32-4.
21. Sweanor D. Regulatory imbalance between medicinal and non-medicinal nicotine. Addiction 2000;95(suppl 1):S25-8.
22. Eliasson B, Taskinen MR, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance. Circulation 1996;94:878-81.
23. Lee TS, Hou X. Nicotine is hazardous to your heart. Chest 1996;109:584-5.
24. US Department of Health and Human Services. Healthy People 2010. Washington DC: Department of Health and Human Services, 2000.
25. CDC. Smoking-attributable mortality and years of potential life lost - United States, 1988. MMWR Morb Mortal Wkly Rep 1991;40:62-3, 69-71.
26. CDC. Cigarette smoking-attributable mortality and years of potential life lost - United States, 1990. MMWR Morb Mortal Wkly Rep 1993;42:645-9.
27. Nelson DE, Kirkendall RS, Lawton RL, et al. Surveillance for smoking-attributable mortality and years of potential life lost, by state - United States, 1990. MMWR Morb Mortal Wkly Rep 1994;43:1-8.
28. Shultz JM, Novotny TE, Rice DP. Quantifying the disease impact of cigarette smoking with SAMMEC II software. Public Health Rep 1991;106:326-33.
29. Malarcher AM, Chrismon JH, Giovino GA, et al. Perspectives in disease prevention and health promotion smoking-attributable mortality and years of potential life lost - United States, 1984. MMWR Morb Mortal Wkly Rep 1997;46:444-51.
30. Thomas AR, Hedberg K, Fleming DW. Comparison of physician based reporting of tobacco attributable deaths and computer derived estimates of smoking attributable deaths, Oregon, 1989 to 1996. Tobacco Control 2001;10:161-4.
31. Fellows JL, Trosclair A. Annual smoking-attributable mortality, years of potential life lost, and economic costs - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2002;51:300-3.
32. Hanson J, Kysar D. The joint failure of economic theory and legal regulation. In: Slovic P, ed. Smoking: risk, perception, and policy. Thousand Oaks, California: Sage Publications, Inc, 2001:229-76.
33. McAllister-Sistilli CG, Caggiula AR, Knopf S, et al. The effects of nicotine on the immune system. Psychoneuroendocrinology 1998;23:175-87.
34. Haapanen A, Koskenvuo M, Kaprio J, et al. Carotid arteriosclerosis in identical twins discordant for cigarette smoking. Circulation 1989;80:10-16.
35. Lindsay GB, Rainey J. Psychosocial and pharmacologic explanations of nicotine's "gateway drug" function. J Sch Health 1997;67:123-6.
36. Navarro HA, Seidler FJ, Schwartz RD, et al. Prenatal exposure to nicotine impairs nervous system development at a dose which does not affect viability or growth. Brain Res Bull 1989;23:187-92.
37. Navarro HA, Seidler FJ, Eylers JP, et al. Effects of prenatal nicotine exposure on development of central and peripheral cholinergic neurotransmitter systems. Evidence for cholinergic trophic influences in developing brain. J Pharmacol Exp Ther 1989;251:894-900.
38. Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? J Pharmacol Exp Ther 1998;285:931-45.
39. Day NL, Richardson GA, Goldschmidt L, et al. Effects of prenatal tobacco exposure on preschoolers' behavior. J Dev Behav Pediatr 2000;21:180-8.
40. Cornelius MD, Ryan CM, Day NL, et al. Prenatal tobacco effects on neuropsychological outcomes among preadolescents. J Dev Behav Pediatr 2001;22:217-25.
41. Ernst M, Moolchan ET, Robinson ML. Behavioral and neural consequences of prenatal exposure to nicotine. J Am Acad Child Adolesc Psychiatry 2001;40:630-41.
42. Slotkin TA. The impact of fetal nicotine exposure on nervous system development and its role in suddent infant death syndrome. In: Benowitz N, ed. Nicotine safety and toxicity. New York: Oxford University Press, 1998:89-97.
43. Oncken CA, Hardardottir H, Smeltzer JS. Human studies of nicotine replacement during pregnancy. In: Benowitz N, ed. Nicotine safety and toxicity. New York: Oxford University Press, 1998:107-116.
44. Centers for Disease Control and Prevention. Best practices for comprehensive tobacco control program - August 1999. Atlanta, Georgia: US Department of Health and Human Services, Centers for Disease Control and Prevention, Office on Smoking and Health, August 1999.
45. Ritch WA, Begay ME. Smoke and mirrors: how Massachusetts diverted millions in tobacco tax revenues. Tobacco Control 2001;10:309-16.
46. DiFranza JR, Rigotti NA. Impediments to the enforcement of youth access laws. Tobacco Control 1999;8:152-5.
47. Mendez D, Warner KE, Courant PN. Has smoking cessation ceased? Expected trends in the prevalence of smoking in the United States. Am J Epidemiol 1998;148:249-58.
48. Mendez D, Warner KE. Smoking prevalence in 2010: why the healthy people goal is unattainable. Am J Public Health 2000;90:401-3.
49. Centers for Disease Control and Prevention. Tobacco control state highlights 2002: impact and opportunity. Atlanta, Georgia: Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2002.
50. Johnston L, O'Malley P, Bachman J. Teen smoking declines sharply in 2002, more than offsetting large increases in the early 1990s. Ann Arbor, Michigan: University of Michigan News and Information Services, 2002.
51. Hilts P. Smokescreen: The truth behind the tobacco industry cover-up. Reading, Massachusetts: Addison-Wesley Publishing Co, 1996:30-37.
52. Kluger R. Ashes to ashes. New York: Alfred A Knopf, 1996:8-16.
53. Henningfield JE, Benowitz NL, Slade J, et al. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tobacco Control 1998;7:281-93.
54. Galbraith JW, Kaiserman M. Taxation, smuggling and demand for cigarettes in Canada: evidence from time-series data. J Health Econ 1997;16:287-301.
55. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 3,094 participants in the lung health study. Lung health study research group. Chest 1996;109:438-45.
56. Benowitz NL, Gourlay SG. Cardiovascular toxicity of nicotine: implications for nicotine replacement therapy. J Am Coll Cardiol 1997;29:1422-31.
57. Benowitz N. Nicotine and cardiovascular disease. In: Benowitz N, ed. Nicotine safety and toxicity. New York: Oxford University Press, 1998:17-27.
58. Rennard SI, Daughton D, Windle J. Toxicity of nicotine replacement in patients with cortonary artery disease. In: Benowitz N, ed. Nicotine safety and toxicity. New York: Oxford University Press, 1998:49-53.
59. Wennmalm A. Cardiovascular effects of cigarette smoke and snuff. In: Benowitz N, ed. Nicotine safety and toxicity. New York: Oxford University Press, 1998:41-7.
60. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Safety 1998;18:297-308.
61. Hipke ME. Green tobacco sickness. South Med J 1993;86:989-92.
62. Bollard T, Ehlers J, Freund E, et al. Green tobacco sickness: occupational nicotine poisoning in tobacco workers. Arch Environ Health 1995;50:384-9.
63. CDC. Ingestion of cigarettes and cigarette butts by children - Rhode Island, January 1994-July 1996. MMWR Morb Mortal Wkly Rep 1997;46:125-8.
64. Woolf A, Burkhart K, Caraccio T, et al. Self-poisoning among adults using multiple transdermal nicotine patches. J Toxicol Clin Toxicol 1996;34:691-8.
65. Heeschen C, Jang JJ, Weis M, et al. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat Med 2001;7:833-9.
66. Jacobi J, Jang JJ, Sundram U, et al. Nicotine accelerates angiogenesis and wound healing in genetically diabetic mice. Am J Pathol 2002;161:97-104.
67. Sayers NM, Drucker DB, Telford DR, et al. Effects of nicotine on bacterial toxins associated with cot death. Arch Dis Child 1995;73:549-51.
68. Chowdhury P, Doi R, Tangoku A, et al. Structural and functional changes of rat exocrine pancreas exposed to nicotine. Int J Pancreatol 1995;18:257-64.
69. Chowdhury P, Rayford PL, Chang LW. Induction of pancreatic acinar pathology via inhalation of nicotine. Proc Soc Exp Biol Med 1992;201:159-64.
70. Cluette-Brown J, Mulligan J, Doyle K, et al. Oral nicotine induces an atherogenic lipoprotein profile. Proc Soc Exp Biol Med 1986;182:409-13.
71. Ashakumary L, Vijayammal PL. Effect of nicotine on lipoprotein metabolism in rats. Lipids 1997;32:311-5.
72. Silcox DH, 3rd, Daftari T, Boden SD, et al. The effect of nicotine on spinal fusion. Spine 1995;20:1549-53.
73. Waldum HL, Nilsen OG, Nilsen T, et al. Long-term effects of inhaled nicotine. Life Sci 1996;58:1339-46.
74. Syversen U, Nordsletten L, Falch JA, et al. Effect of lifelong nicotine inhalation on bone mass and mechanical properties in female rat femurs. Calcif Tissue Int 1999;65:246-9.
75. Loennechen JP, Nilsen OG, Arbo I, et al. Chronic exposure to carbon monoxide and nicotine: endothelin ET(A) receptor antagonism attenuates carbon monoxide-induced myocardial hypertrophy in rat. Toxicol Appl Pharmacol 2002;178:8-14.
76. Dempsey DA, Benowitz NL. Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf 2001;24:277-322.
77. Cancer Prevention Study II. The American Cancer Society Prospective Study. Stat Bull Metrop Insur Co 1992;73:21-9.
78. Malarcher AM, Schulman J, Epstein LA, et al. Methodological issues in estimating smoking-attributable mortality in the United States. Am J Epidemiol 2000;152:573-84.
79. Thun MJ, Apicella LF, Henley SJ. Smoking vs other risk factors as the cause of smoking-attributable deaths: confounding in the courtroom. JAMA 2000;284:706-12.